Overview

Phase I Study of Sorafenib Dosed Continuously With Cyclophosphamide and Doxorubicin

Status:
Completed
Trial end date:
2010-03-01
Target enrollment:
Participant gender:
Summary
Study to access the safety, levels of drug in the blood and tumor effects of sorafenib dosed daily combined with Cyclophosphamide and Doxorubicin in cancer patients
Phase:
Phase 1
Details
Lead Sponsor:
Bayer
Treatments:
Cyclophosphamide
Doxorubicin
Liposomal doxorubicin
Niacinamide
Sorafenib